Loading…
Strategic Analysis
This CSA call aims to position Europe as a global leader in AGI for healthcare by fostering a multidisciplinary stakeholder community, creating a roadmap for frontier AI models, and ensuring alignment with EU regulatory and ethical frameworks. Winning proposals will emphasize community-building, regulatory foresight, and data interoperability while demonstrating clear pathways to scalable, trustworthy AGI solutions that enhance personalised medicine and healthcare efficiency.
Community building: build a large-scale and diverse pan-European community of stakeholders with the multidisciplinary expertise united as required to develop the next generation of frontier AI models for healthcare, towards AGI for healthcare, with a view to leveraging as a community the potential of AI Factories. Where relevant, this should build on and strengthen existing EU-funded communities and networks, and could pave the way for a formalised long-term collaboration under one of the available EU instruments.
Roadmap creation: review previous research to identify the most promising AI models and model development approaches. In addition, risk assess and review evidence on safety and efficacy of existing AI models with reference to the AI Act, related regulatory provisions (including any jurisprudence) and ethical and security considerations, so that frontier AI model development can proceed on a well-informed basis. Finally, create a roadmap for developing the next generation of frontier AI models.
Dataset identification, curation, expansion and use: i) identification: identify the most suitable existing datasets for the development of frontier AI models for healthcare, ii) curation: identify how to validate the datasets, ensure dataset interoperability, and convert datasets into formats suitable for frontier AI model development, iii) expansion: identify additional datasets and/or annotations required for frontier AI model development, especially to ensure that datasets are representative and iv) use: identify methods and required infrastructure to allow privacy-preserving use and further expansion of the datasets in alignment with and through the EHDS.
Frontier AI model preparatory activities: mapping approaches for training and evaluating frontier AI models (e.g. approaches to combine foundation models for life sciences and healthcare delivery in order to develop more advanced and multidisciplinary models towards personalised medicine). The approaches should cover all trustworthy AI aspects.
Researchers and innovators benefit from an improved understanding of how to develop and use the next generation of frontier Artificial Intelligence (AI) models for healthcare, including how to leverage AI Factories and how to combine and expand the capabilities of existing foundation models towards inclusive and personalised medicine.
Researchers and innovators benefit from an improved understanding of how to leverage highly heterogeneous and multimodal health data spanning a range of anatomical scales (i.e. the micro to the macro level).
Multidisciplinary stakeholders have access to a collaboratively created roadmap for developing the next generation of frontier AI models for healthcare, towards Artificial General Intelligence (AGI) for healthcare.
Europe’s scientific and technological expertise and know-how, its capabilities for innovation in new tools, technologies and digital solutions, and its ability to take-up, scale-up and integrate innovation in healthcare is world-class.
Citizens benefit from targeted and faster research resulting in safer, more sustainable, efficient, cost-effective, accessible and affordable tools, technologies and digital solutions for improved (personalised) disease prevention, diagnosis, treatment and monitoring for better patient outcome and wellbeing, in particular through increasingly shared health resources (interoperable data, infrastructure, expertise, citizen/patient driven co-creation).
The EU gains high visibility and leadership in terms of health technology development, including through international cooperation.
The burden of diseases in the EU and worldwide is reduced through the development and integration of innovative diagnostic and therapeutic approaches, personalised medicine approaches, digital and other people-centred solutions for healthcare.
Both the productivity of health Research and Innovation, and the quality and outcome of healthcare is improved thanks to the use of health data and innovative analytical tools, such as AI supported decision-making, in a secure, ethical and inclusive manner, respecting individual integrity and underpinned with public acceptance and trust.
Citizens trust and support the opportunities offered by innovative technologies for healthcare, based on expected health outcomes and potential risks involved.
Artificial Intelligence Strategy
highStrategy for European Life Sciences
highEuropean Health Data Space (EHDS) regulation
highAI Act
highEthics guidelines for trustworthy AI
highBiotechnology and Biomanufacturing Communication
mediumSpecific requirements
Topic-specific consortium
Many CSA topics require a broader consortium than the general-annex minimum. The call-specific Eligibility and admissibility conditions override the general annex.
Restricted beneficiary type
Many CSA calls are reserved for specific beneficiary types (national funding agencies, research infrastructures, standards bodies). Check the call.
Coordination/support activities only
CSA funds coordination, networking, policy support, dissemination, training. Not research activities per se.
Gender Equality Plan
GEP eligibility criterion applies to public bodies, research organisations, higher education institutions from MS/AC.
Geographic restriction to Member States and Associated Countries
Participation is limited to legal entities established in Member States and Associated Countries, and proposals including entities established outside this scope will be ineligible.
Ownership control and guarantee requirements
Entities established in an eligible country but directly or indirectly controlled by a non-eligible country or entity may not participate unless positively assessed guarantees demonstrated by their eligible country of establishment prove their participation will not negatively impact the Union's strategic assets, interests, autonomy, or security.
Exclusion of high-risk network suppliers
Entities assessed as high-risk suppliers of mobile network communication equipment (or entities fully or partially owned or controlled by them) cannot submit guarantees and are not eligible to participate as beneficiaries, affiliated entities, and associated partners.
1. Admissibility conditions — , proposal page limit and layout Admissibility conditions are described in Annex A and Annex E of the Horizon Europe Work Programme General Annexes. Proposal page limits and layout are described in Part B of the Application Form available in the Submission System.
2. Eligible Countries — Eligible countries are described in Annex B of the Work Programme General Annexes. A number of non-EU/non-Associated Countries that are not automatically eligible for funding have made specific provisions for making funding available for their participants in Horizon Europe projects. See the information in the Horizon Europe Programme Guide .
3. Other Eligibility Conditions — In order to achieve the expected outcomes, and safeguard the Union’s strategic assets, interests, autonomy, or security, it is important to avoid a situation of technological dependency on a non-EU source, in a global context that requires the EU to take action to build on its strengths, and to carefully assess and address any strategic weaknesses, vulnerabilities and high-risk dependencies which put at risk the attainment of its ambitions. For this reason, participation is limited to legal entities established in Member States and Associated Countries. Proposals including entities established in countries outside the scope specified in the topic will be ineligible. For the duly justified and exceptional reasons listed in the paragraph above, in order to guarantee the protection of the strategic interests of the Union and its Member States, entities established in an eligible country listed above, but which are directly or indirectly controlled by a non-eligible country or by a non-eligible country entity, may not participate in the action unless it can be demonstrated, by means of guarantees positively assessed by their eligible country of establishment, that their participation to the action would not negatively impact the Union’s strategic assets, interests, autonomy, or security. Entities assessed as high-risk suppliers of mobile network communication equipment within the meaning of ‘restrictions for the protection of European communication networks’ (or entities fully or partially owned or controlled by a high-risk supplier) cannot submit guarantees.[[The guarantees shall in particular substantiate that, for the purpose of the action, measures are in place to ensure that: a) control over the applicant legal entity is not exercised in a manner that retrains or restricts its ability to carry out the action and to deliver results, that imposes restrictions concerning its infrastructure, facilities, assets, resources, intellectual property or know-how needed for the purpose of the action, or that undermines its capabilities and standards necessary to carry out the action; b) access by a non-eligible country or by a non-eligible country entity to sensitive information relating to the action is prevented; and the employees or other persons involved in the action have a national security clearance issued by an eligible country, where appropriate; c) ownership of the intellectual property arising from, and the results of, the action remain within the recipient during and after completion of the action, are not subject to control or restrictions by non-eligible countries or non-eligible country entity, and are not exported outside the eligible countries, nor is access to them from outside the eligible countries granted, without the approval of the eligible country in which the legal entity is established. ]] If projects use satellite-based earth observation, positioning, navigation and/or related timing data and services, beneficiaries must make use of Copernicus and/or Galileo/EGNOS (other data and services may additionally be used). Subject to restrictions for the protection of European communication networks. Other eligibility conditions are described in Annex B of the Work Programme General Annexes.
4. Financial and operational capacity and exclusion — Financial and operational capacity and exclusion are described in Annex C of the Work Programme General Annexes.
5a. Evaluation and award: Award criteria, scoring and thresholds — Award criteria, scoring and thresholds are described in Annex D of the Work Programme General Annexes.
5b. Evaluation and award: Submission and evaluation processes — The thresholds for each criterion will be 4 (Excellence), 4 (Impact) and 4 (Implementation). The cumulative threshold will be 12. Submission and evaluation processes are described in Annex F of the Work Programme General Annexes and the Online Manual .
5c. Evaluation and award: Indicative timeline for evaluation and grant agreement — Indicative timeline for evaluation and grant agreement are described in Annex F of the Work Programme General Annexes.
6. Legal and financial set-up of the grants — Eligible costs will take the form of a lump sum as defined in the Decision of 7 July 2021 authorising the use of lump sum contributions under the Horizon Europe Programme – the Framework Programme for Research and Innovation (2021-2027) – and in actions under the Research and Training Programme of the European Atomic Energy Community (2021-2025) [[This decision is available on the Funding and Tenders Portal, in the reference documents section for Horizon Europe, under ‘Simplified costs decisions’ or through this link: https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/horizon/guidance/ls-decision_he_en.pdf ]]. Legal and financial set-up of the grants are described in Annex G of the Work Programme General Annexes.
Specific conditions are described in the specific topic of the Work Programme. Application and evaluation forms and
Application and evaluation form templates Standard application form (HE CSA) - the application form specific to this call is available in the Submission System Standard evaluation form (HE CSA) - will be used with the necessary adaptations Guidance HE Programme Guide Model Grant Agreement (MGA) Lump Sum MGA Call-specific instructions Detailed budget table (HE LS) Guidance: "Lump sums - what do I need to know?" Ownership control declaration Additional documents HE Main Work Programme 2026-2027 – 1. General Introduction HE Main Work Programme 2026-2027 – 4. Health HE Main Work Programme 2026-2027 – 15. General Annexes HE Programme Guide HE Framework Programme 2021/695 HE Specific Programme Decision 2021/764 EU Financial Regulation 2024/2509 Decision authorising the use of lump sum contributions under the Horizon Europe Programme Rules for Legal Entity Validation, LEAR Appointment and Financial Capacity Assessment EU Grants AGA — Annotated Model Grant Agreement Funding & Tenders Portal Online Manual Funding & Tenders Portal Terms and Conditions Funding & Tenders Portal Privacy Statement
Everything the call asks for, seen from the call's point of view. Each line shows what answers it, and which partner carries it.
This matrix lists everything the call asks for: outcomes, impacts, scope, the requirements buried in the call text, and policy alignment. Sign up free and GrantForge tracks each line against the concept you build.
| Requirement | Covered by | Carried | Status |
|---|---|---|---|
| Scope activities | |||
| SC1Community building: build a large-scale and diverse pan-European community of stakeholders with the multidisciplinary expertise united as required to develop the next generation of frontier AI models for healthcare, towards AGI for healthcare, with a view to leveraging as a community the potential of AI Factories. Where relevant, this should build on and strengthen existing EU-funded communities and networks, and could pave the way for a formalised long-term collaboration under one of the available EU instruments. | · | · | Sign up to track |
| SC2Roadmap creation: review previous research to identify the most promising AI models and model development approaches. In addition, risk assess and review evidence on safety and efficacy of existing AI models with reference to the AI Act, related regulatory provisions (including any jurisprudence) and ethical and security considerations, so that frontier AI model development can proceed on a well-informed basis. Finally, create a roadmap for developing the next generation of frontier AI models. | · | · | Sign up to track |
| SC3Dataset identification, curation, expansion and use: i) identification: identify the most suitable existing datasets for the development of frontier AI models for healthcare, ii) curation: identify how to validate the datasets, ensure dataset interoperability, and convert datasets into formats suitable for frontier AI model development, iii) expansion: identify additional datasets and/or annotations required for frontier AI model development, especially to ensure that datasets are representative and iv) use: identify methods and required infrastructure to allow privacy-preserving use and further expansion of the datasets in alignment with and through the EHDS. | · | · | Sign up to track |
| SC4Frontier AI model preparatory activities: mapping approaches for training and evaluating frontier AI models (e.g. approaches to combine foundation models for life sciences and healthcare delivery in order to develop more advanced and multidisciplinary models towards personalised medicine). The approaches should cover all trustworthy AI aspects. | · | · | Sign up to track |
| Expected outcomes | |||
| EO1Researchers and innovators benefit from an improved understanding of how to develop and use the next generation of frontier Artificial Intelligence (AI) models for healthcare, including how to leverage AI Factories and how to combine and expand the capabilities of existing foundation models towards inclusive and personalised medicine. | · | · | Sign up to track |
| EO2Researchers and innovators benefit from an improved understanding of how to leverage highly heterogeneous and multimodal health data spanning a range of anatomical scales (i.e. the micro to the macro level). | · | · | Sign up to track |
| EO3Multidisciplinary stakeholders have access to a collaboratively created roadmap for developing the next generation of frontier AI models for healthcare, towards Artificial General Intelligence (AGI) for healthcare. | · | · | Sign up to track |
| Other requirements | |||
| REQ1Broad representation of multidisciplinary stakeholders in consortiumProposals must ensure multidisciplinary approaches and broad representation of stakeholders in the consortium, such as healthcare professionals, patients, biomedical scientists, AI developers, data engineers, and ethics experts. | · | · | Sign up to track |
| REQ2Synergies with GenAI4EU projectsThe action should take into account the results of other relevant projects on AI in health, specifically HORIZON-HLTH-2025-01-CARE-01 and HORIZON-HLTH-2025-01-TOOL-03. | · | · | Sign up to track |
| REQ3Leveraging Digital Europe Programme infrastructures and AI FactoriesProposals must leverage AI Factories and specialised health data infrastructures funded under the Digital Europe Programme, biobanks, relevant ERICs, and EHDS infrastructure funded under the EU4Health Programme. | · | · | Sign up to track |
| REQ4Cross-project cooperation within Horizon EuropeThe Commission encourages cooperation between EU-funded projects via networking, joint workshops, knowledge exchange, and joint communication across topics, Clusters, or Pillars (including Pillar I research infrastructures, Pillar III EIC challenges, and Cluster 4). | · | · | Sign up to track |
| REQ5Mandatory use of Copernicus and Galileo/EGNOS dataIf projects use satellite-based earth observation, positioning, navigation, or timing data and services, beneficiaries must make use of Copernicus and/or Galileo/EGNOS. | · | · | Sign up to track |
| REQ6Compliance with ethical, legal, and trustworthy AI standardsFrontier AI mapping and roadmap activities must cover all trustworthy AI aspects, addressing ethical and security considerations, safety and efficacy risk assessments, and compliance with the AI Act. | · | · | Sign up to track |
| Expected impacts | |||
| EI1Europe’s scientific and technological expertise and know-how, its capabilities for innovation in new tools, technologies and digital solutions, and its ability to take-up, scale-up and integrate innovation in healthcare is world-class. | · | · | Sign up to track |
| EI2Citizens benefit from targeted and faster research resulting in safer, more sustainable, efficient, cost-effective, accessible and affordable tools, technologies and digital solutions for improved (personalised) disease prevention, diagnosis, treatment and monitoring for better patient outcome and wellbeing, in particular through increasingly shared health resources (interoperable data, infrastructure, expertise, citizen/patient driven co-creation). | · | · | Sign up to track |
| EI3The EU gains high visibility and leadership in terms of health technology development, including through international cooperation. | · | · | Sign up to track |
| EI4The burden of diseases in the EU and worldwide is reduced through the development and integration of innovative diagnostic and therapeutic approaches, personalised medicine approaches, digital and other people-centred solutions for healthcare. | · | · | Sign up to track |
| EI5Both the productivity of health Research and Innovation, and the quality and outcome of healthcare is improved thanks to the use of health data and innovative analytical tools, such as AI supported decision-making, in a secure, ethical and inclusive manner, respecting individual integrity and underpinned with public acceptance and trust. | · | · | Sign up to track |
| EI6Citizens trust and support the opportunities offered by innovative technologies for healthcare, based on expected health outcomes and potential risks involved. | · | · | Sign up to track |
| Underlying policies | |||
| POL1Artificial Intelligence StrategyThe EU AI Strategy promotes the development and adoption of trustworthy AI, with a focus on high-impact sectors like healthcare. It emphasises ethical, secure, and human-centric AI. | · | · | Sign up to track |
| POL2Strategy for European Life SciencesThis strategy seeks to enhance Europe's leadership in life sciences, including the integration of AI and digital technologies to drive innovation in healthcare and personalised medicine. | · | · | Sign up to track |
| POL3European Health Data Space (EHDS) regulationEHDS aims to facilitate the secure and interoperable use of health data across the EU, enabling better healthcare delivery, research, and innovation. | · | · | Sign up to track |
| POL4AI ActThe AI Act establishes a regulatory framework for AI systems, categorising them by risk and setting requirements for transparency, safety, and accountability, particularly for high-risk applications like healthcare. | · | · | Sign up to track |
| POL5Ethics guidelines for trustworthy AIThese guidelines provide a framework for developing AI systems that are lawful, ethical, and robust, with a focus on human agency, fairness, transparency, and accountability. | · | · | Sign up to track |
The binding rules of this call. Items marked auto are verified by GrantForge from the call and the template. The others are yours to confirm.
LMIC entities auto-eligible
Low/middle-income country entities are automatically eligible for funding.
Topic-specific consortium
Many CSA topics require a broader consortium than the general-annex minimum. The call-specific Eligibility and admissibility conditions override the general annex.
Restricted beneficiary type
Many CSA calls are reserved for specific beneficiary types (national funding agencies, research infrastructures, standards bodies). Check the call.
Coordination/support activities only
CSA funds coordination, networking, policy support, dissemination, training. Not research activities per se.
Gender Equality Plan
GEP eligibility criterion applies to public bodies, research organisations, higher education institutions from MS/AC.
Geographic restriction to Member States and Associated Countries
Participation is limited to legal entities established in Member States and Associated Countries, and proposals including entities established outside this scope will be ineligible.
Ownership control and guarantee requirements
Entities established in an eligible country but directly or indirectly controlled by a non-eligible country or entity may not participate unless positively assessed guarantees demonstrated by their eligible country of establishment prove their participation will not negatively impact the Union's strategic assets, interests, autonomy, or security.
Exclusion of high-risk network suppliers
Entities assessed as high-risk suppliers of mobile network communication equipment (or entities fully or partially owned or controlled by them) cannot submit guarantees and are not eligible to participate as beneficiaries, affiliated entities, and associated partners.
Nothing to show for this call yet.